Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Depreciation & Amortization (CF): 2011-2024

Historic Depreciation & Amortization (CF) for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $75.7 million.

  • Ptc Therapeutics' Depreciation & Amortization (CF) rose 71.28% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.7 million, marking a year-over-year decrease of 78.16%. This contributed to the annual value of $75.7 million for FY2024, which is 68.02% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Depreciation & Amortization (CF) is $75.7 million, which was down 68.02% from $236.6 million recorded in FY2023.
  • Ptc Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $236.6 million for FY2023, and its period low was $43.5 million during FY2020.
  • Over the past 3 years, Ptc Therapeutics' median Depreciation & Amortization (CF) value was $128.8 million (recorded in 2022), while the average stood at $147.0 million.
  • In the last 5 years, Ptc Therapeutics' Depreciation & Amortization (CF) surged by 100.89% in 2022 and then slumped by 68.02% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $43.5 million in 2020, then skyrocketed by 47.47% to $64.1 million in 2021, then surged by 100.89% to $128.8 million in 2022, then soared by 83.64% to $236.6 million in 2023, then crashed by 68.02% to $75.7 million in 2024.